Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin A + Ropivacaïne vs Ropivacaïne Alone for Myofascial Pelviperineal Pain
NCT01967524Phase 3Completed
- Sponsor
- CHU de Nantes
- Start
- Sep 2013
- Primary completion
- Aug 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin type A in myofascial pelvic pain syndrome (MPPS) (2 arms), sponsored by CHU de Nantes. Primary endpoint: Patient Global Impression of Improvement at 2 months. Started Sep 2013; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
myofascial pelvic pain syndrome (MPPS)
Beyond the preview
Go deeper on NCT01967524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01967524.